Avidity Biosciences: Unique Antibody-Oligonucleotide Conjugate Technology

Summary

  • Avidity Biosciences' stock was up 55% last week after releasing preliminary data from a Phase 1/ 2 study of its antibody-oligonucleotide technology candidate in treating myotonic dystrophy type 1.
  • The next price-moving catalyst is the updated Phase 1/2 MARINA trial data in 2023 (likely in mid-2023).
  • Other pipeline indications include Duchenne muscular dystrophy and facioscapulohumeral dystrophy.
  • We're currently running a sale at my private investing ideas service, Vasuda Healthcare Analytics, where members get access to portfolios, market alerts, real-time chat, and more. Learn More »

Ribonucleic acid strands consisting of nucleotides - 3d illustration

Christoph Burgstedt

Avidity Biosciences (NASDAQ:RNA) was founded in 2012 and is based in San Diego, California.

The company's stock was up 55% last week after releasing preliminary data from a Phase 1/ 2 study of its antibody-oligonucleotide technology candidate in treating myotonic

Premium service reviews

"The best I have ever seen in the biotech space...I have been in the biotech investing space for a while and have not seen a service like the one Dr. Bhavneesh provides."

"Great service with in-depth research on biotech stocks. I appreciate that Dr. Sharma will take the time to review and publish reports/updates on stocks that members request. Biotech investing is very complex and it's great to have someone so knowledgeable guiding us."

This article was written by

7.51K Followers

With a robust academic background including an MBA in Finance from NYU-Stern, and an MD from Delhi University, my journey in the financial world has been diverse and enriching. My postgraduate training in medicine was conducted at Harvard and Cornell affiliated hospitals, thus laying a solid foundation for my current expertise.

As a registered investment advisor and professional money manager, I bring nearly a decade of experience in writing about income investing and biotech/pharma investing. My role at Vasuda Healthcare Analytics isn't just about leading; it's about fostering a community where breakthrough investment ideas in the biotech/pharma industry are not only shared but thrive.

My contributions stand out for their depth and breadth, offering exclusive analysis of income investing and long-term takeover potential biotech/pharma stocks. I specialize in identifying both short-term, catalyst-driven opportunities and crafting long-term investment strategies. Additionally, I provide detailed biotech analysis tailored to specific requests, ensuring that my audience stays ahead in the fast-evolving biotech sector.

Subscribers benefit from regular portfolio trade alerts and an interactive chat feature, fostering a dynamic dialogue and addressing any questions. Through my insights and guidance, investors can navigate the complexities of biotech investing with greater confidence and success.

I authored the top-selling book titled, 'Winning Strategies For Biotech Investing', which is available on Amazon.

I am also an instructor for an Udemy course on biotech investing.

Specialties:

High Growth Biotech/Pharma Investment Ideas, Exclusive Stock Analysis, Short-Term Catalyst-Driven and Long-Term Investment Strategies, Custom Biotech Analysis upon Request, Portfolio Trade Alerts and Interactive Dialogue.

Learn more

Analyst’s Disclosure:I/we have a beneficial long position in the shares of RNA either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About RNA Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on RNA

Related Stocks

SymbolLast Price% Chg
RNA
--